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Abstract 
Background: MicroRNAs (miRNAs) are small RNAs regulating gene expression post‑transcriptionally. While acquired 
changes of miRNA and mRNA profiles in cancer have been extensively studied, little is known about expression 
changes of circulating miRNAs and messenger RNAs (mRNA) in monogenic constitutional anomalies affecting several 
organ systems, like Marfan syndrome (MFS). We performed integrated miRNA and mRNA expression profiling in blood 
samples of Marfan patients in order to investigate deregulated miRNA and mRNA networks in these patients which 
could serve as potential diagnostic and prognostic tools for MFS therapy.
Methods: MiRNA and mRNA expression profiles were determined in blood samples from MFS patients (n = 7) and 
from healthy volunteer controls (n = 7) by microarray analysis. Enrichment analyses of altered mRNA expression were 
identified using bioinformatic tools.
Results: A total of 28 miRNAs and 32 mRNAs were found to be significantly altered in MFS patients compared to 
controls (> 2.0‑fold change, adjusted P < 0.05). The expression of 11 miRNA and 6 mRNA candidates was validated by 
RT‑qPCR in an independent cohort of 26 MFS patients and 26 matched HV controls. Significant inverse correlations 
were evident between 8 miRNAs and 5 mRNAs involved in vascular pathology, inflammation and telomerase regula‑
tion. Significant positive correlations were present for 7 miRNAs with age, for 2 miRNAs with the MFS aortic root status 
(Z‑score) and for 7 miRNAs with left ventricular end‑diastolic diameter in MFS patients. In addition, miR‑331‑3p was 
significantly up‑regulated in MFS patients without mitral valve prolapse (MVP) as compared with patients with MVP.
Conclusions: Our data show deregulated gene and miRNA expression profiles in the peripheral blood of MFS 
patients, demonstrating several candidates for prognostic biomarkers for cardiovascular manifestations in MFS as well 
as targets for novel therapeutic approaches. A deregulation of miRNA expression seems to play an important role in 
MFS, highlighting the plethora of effects on post‑transcriptional regulation of miRNAs and mRNAs initiated by consti‑
tutional mutations in single genes.
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Background
Marfan syndrome (MFS, OMIM #154700) is a con-
nective tissue disorder with an estimated incidence of 
1:5000 individuals, across all ethnic backgrounds [1, 2]. 
Although an autosomal dominant inheritance of MFS 
typically appears in affected multi-generation families, 
approximately 25% of cases have the disorder as the 
result of a de novo mutation [3]. The phenotypic vari-
ability of this disorder ranges from minor stigmata to 
life-threatening manifestations, typically involving the 
cardiovascular (thoracic aortic aneurysms (TAA) and 
dissections), ocular (ectopia lentis), and musculoskel-
etal system (tall stature with arachnodactyly) [4–6]. 
Cardiovascular manifestations are responsible for the 
high morbidity in individuals with MFS and can include 
dilation of the ascending aorta, pulmonary artery dila-
tion, and mitral valve prolapse [6]. Mutations in Fibril-
lin-1 (FBN1) were identified as the cause of MFS [5]. As 
FBN1 is a constituent of the connective tissue in a wide 
range of organs, decreased mechanical stability caused by 
mutations in FBN1 has pleiotropic effects. Pleiotropy was 
introduced by Plate in 1910 to describe multiple pheno-
typic effects of a single genetic trait [7]. Although there 
are 3077 known mutations in the FBN1 gene (UMD-
FBN1 listed in the database: http://www.umd.be/FBN1/, 
updated on August 28, 2014) and more than 1500 differ-
ent disease-causing FBN1 mutations, there is no single 
FBN1 genotype feature that qualifies as a reliable pre-
dictor of the clinical severity and long-term course of 
MFS. Even within a given family with an identical FBN1 
mutation, there is considerable variation as to the sever-
ity of manifestation, pointing towards complex interac-
tions of FBN1 with other genes and their products [4, 
6, 8]. Currently, methods for predicting the prognosis of 
Marfan-related cardiovascular manifestations are lim-
ited. However, in several pathologies, microRNAs (miR-
NAs) have emerged in recent years as a promising new 
type of biomarker for the prognosis of disease, including 
initial data on MFS and aortic disease [9, 10]. MiRNAs 
are a class of non-coding RNAs of 18–22 nucleotides in 
length that regulate gene expression post-transcription-
ally via sequence-specific interaction with the 3′ untrans-
lated region (UTR) of a target gene’s mRNA, resulting in 
inhibition of translation and/or mRNA degradation [7]. 
Altered expression of miRNA has been associated with 
many human diseases, including MFS [9, 11]. Recently, 
it was reported that miR-29b is associated with vascu-
lar remodeling and subsequent aneurysm development 
characteristic of MFS and that this miRNA plays an 
important role in regulating aortic wall apoptosis and 
extracellular matrix abnormalities in MFS [11]. In addi-
tion to miRNA expression analysis, genome-wide mRNA 
expression analyses of skin fibroblast cultures from 
individuals with known FBN1 mutations and controls has 
been performed [12]. In tissue of MFS patients, however, 
investigations of miRNAs as well as mRNAs are still lack-
ing. Thus, it is conceivable that in addition to an entire 
miRNome expression profiling, the search for miRNAs 
whose expression inversely correlates with the expression 
of mRNA targets may demonstrate another layer of the 
molecular diversity of this pleiotropic syndrome and may 
potentially be a useful diagnostic and prognostic tool for 
MFS therapy and treatment. A crucial clinical challenge 
are still insufficient indication criteria for preventive aor-
tic replacement that call for biological parameters beyond 
the current restriction to ultrasonographic and magnetic 
resonance imaging (MRI) measurements. Therefore, we 
investigated differences in miRNA and mRNA expression 
patterns between MFS patients and healthy volunteer 
[13] controls. We furthermore performed an integrated 
analysis across all samples to identify mRNA targets 
of deregulated miRNAs. To our knowledge, this is the 
first large-scale investigation of the association between 
miRNA-related mRNAs in patients with MFS.
Methods
Patient samples
The study was conducted in accordance with the Decla-
ration of Helsinki and approved by the locally appointed 
Ethics committee [Institutional Review Board (Num-
ber: EA2/131/10)]. Informed consent was obtained from 
all patients and HV controls. A cohort of 34 patients 
in whom the clinical diagnosis of classical MFS was 
made according to the current Ghent nosology [6] was 
assessed for the ocular, musculoskeletal, and cardiovas-
cular features by an ophthalmologist, a pediatrician, a 
cardiologist, and a clinical geneticist. Two-dimensional 
echocardiography was used to measure the diameter 
of the ascending aorta which was used to determine 
the patients’ Z-score. Moreover the left ventricular 
end-diastolic diameter (LVEDD) and the presence of a 
mitral valve prolapse (MVP) were assessed by echocar-
diography. The patient cohort included 15 males and 19 
females with a mean age of 27.62 years (standard devia-
tion ± 15.66 years) and confirmed FBN1 mutation which 
were compared with age- and sex matched HV controls 
(n = 34). All Marfan patients were on Angiotensin recep-
tor blockers. Beta blockers or ACE inhibitors had been 
added to the medication depending on the level of arte-
rial hypertension or the presence of other cardiovascular 
morbidities. In all HV controls, a physical examination 
including measurement of blood pressure and transcu-
taneous oxygen saturation as well as two-dimensional 
echocardiography was performed to rule out any con-
founding cardiac and extracardiac abnormalities. At 
the time of enrolment, none of the controls took any 
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medication or had elevated blood pressure. Additionally, 
none of them had any heart abnormality on the echocar-
diogram. In all patients and HV controls 2.5  mL of 
venous blood from the cubital vein was collected in PAX-
gene blood tubes (BD Biosciences, San Jose, California, 
United States). All PAXgene blood tubes were stored at 
room temperature for 2 h to ensure complete lysis of the 
blood cells before they were stored at − 20 °C until RNA 
isolation. MiRNA raw data were acquired from samples 
which had previously been used for a related study pub-
lished by our group [9].
RNA isolation
Total RNA including miRNAs of all MFS patients and 
HV controls was isolated with the PAXgene miRNA 
blood kit using the QIAcube™ automated isolation 
instrument according to the manufacturer’s instructions 
(Qiagen, Hilden, Germany). The RNA concentration and 
purity were confirmed by the spectrophotometric ratio 
using absorbance measurements at wavelengths of 260 
and 280  nm on a NanoDrop-2000 (Thermo Scientific, 
Waltham, Massachusetts, United States). The integrity 
of the isolated RNA was analyzed on a RNA Nano 6000 
chip using an Agilent Bioanalyzer (Agilent Technologies, 
Santa Clara, California, United States). Genomic DNA 
contamination was removed, and conventional poly-
merase chain reaction (PCR) was carried out to exclude 
any residual DNA in the samples as previously described 
[14]. Moreover, the RNA-based RT-qPCRs were carried 
out using predesigned exon spanning primers (Qiagen).
Gene expression microarray assay analysis
MRNA expression profiles of MFS (n = 8) and HV con-
trols (n = 8) samples were performed with SurePrint G3 
Human Gene Expression v2 8x60K microarrays con-
taining 50,599 biological features (Agilent Technologies, 
Santa Clara, CA, United States). All procedures were car-
ried out according to the manufacturer’s protocol. Briefly, 
100 ng total RNA from each sample was reversely tran-
scribed, amplified and labeled using the LowInput Quick-
Amp Labeling Kit (Agilent). Quantification and specific 
activity of labeled complementary RNA (cRNA) was 
evaluated using the NanoDrop-2000 spectrophotometer 
(Thermo Scientific) to ensure that labeled cRNA was of 
sufficient quality for hybridization. A total of 600  ng of 
cRNA was then applied to the microarray slide per the 
manufacturer’s instructions and hybridized in a rotating 
oven for 17 h at 65 °C and 10 rpm. Arrays were washed 
and then scanned using a DNA Microarray Scanner (Agi-
lent). Feature extraction software was utilized to extract 
gene expression data (Agilent).
MiRNA microarray assay analysis
We used the Sureprint G3 Human miRNA 8x60K 
microarrays raw data of 8 MFS and 8 HV controls [9]. 
MiRNA expression profiles were performed with Sure-
print G3 Human miRNA 8x60K microarrays containing 
40 replicates of 1205 miRNAs of miRBase v16 (Agi-
lent). All procedures were carried out according to the 
manufacturer’s protocol. Briefly, 100 ng total RNA from 
each sample was processed using the miRNA Com-
plete Labeling and Hyb Kit (Agilent) to generate fluo-
rescently labeled miRNA. The labeled RNA was then 
applied to the microarray slide per the manufacturer’s 
instructions and hybridized in a rotating oven for 20 h 
at 55  °C and 20  rpm. Arrays were washed and then 
scanned using a DNA Microarray Scanner (Agilent). 
Feature extraction software was utilized to extract gene 
expression data (Agilent).
Reverse transcription and quantitative real‑time PCR
Expression of selected mRNAs and miRNAs in MFS and 
HV controls was determined by real-time quantitative 
PCR (RT-qPCR) using the StepOnePlus™ Real-Time PCR 
System (Applied Biosystems, Foster City, CA, United 
States) and the miScript PCR System that contain miS-
cript RT II Kit with 5× miScript HiFlex Buffer and SYBR 
Green PCR along with the QuantiTect and miScript 
Primer Assays (Qiagen). All procedures were carried 
out according to the manufacturer’s recommendations. 
Using a cohort of independent MFS patients (n = 26) and 
HV controls (n = 26), 13 differentially expressed mRNAs 
(CLU, CRYAA, CTNNA1, DYSF, GBP2, ITGB3, LIMK2, 
MFN2, MMP9, MX1, SIRPB1, POT1 and SOCS3) and 
18 differentially expressed miRNAs (miR-1228, miR-
1234-3p, miR-1275, miR-139-3p, miR-151-5p, miR-200c, 
miR-24, miR-30e, miR-324-5p, miR-940, miR-3616-3p, 
miR-362-5p, miR-500b, miR-502-3p, miR-564, miR-627, 
miR-874 and miR-331-3p) were selected to validate the 
array results. In brief, 400  ng of total RNA were con-
verted into complementary DNA (cDNA). The result-
ing cDNA was then diluted to have 1.5 and 0.5  ng/
µL for mRNA and miRNA, respectively. All RT-qPCR 
experiments were performed using the Liquid Handling 
Robot QIAgility™ (Qiagen) before performing RT-qPCR. 
β-Actin and RNU6B small nuclear RNA (snRNA) primer 
assays (Qiagen) were chosen as endogenous references 
for mRNA and miRNA normalization. Moreover, a no 
template control (NTC) and no reverse transcriptase 
control (RT negative) were included in each mRNA and 
miRNA in each run, and a miRNA reverse transcription 
control (miRTC) was performed to assess the perfor-
mance of the reverse transcription reaction by detecting 
template synthesized from the kit’s built-in control RNA 
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(Qiagen). Melting curve analysis was used to control for 
the specificity of RT-qPCR products.
Overrepresentation analysis
To evaluate the significance of the identified differentially 
expressed genes, the Protein ANalysis THrough Evolu-
tionary Relationships (PANTHER) Classification System 
was used to categorize the differentially expressed genes 
according to PANTHER protein class, Gene Ontology 
(GO) Molecular Function, GO Biological Process and 
GO cellular components annotations [15]. For each bio-
logical pathway and/or process, the difference between 
the observed fraction of genes in that pathway and/or 
process and the number expected by chance was tested 
using Fisher’s exact test. P values were adjusted using a 
Bonferroni correction.
Statistical analysis
The statistical analysis was performed using R (version 
3.4.0) to analyze the differences in mRNA and miRNA 
expression patterns in the MFS patients and HV controls. 
Raw data generated by the Agilent Feature Extraction 
image analysis software was normalized by variance sta-
bilizing normalization (vsn) [16] and quantile normali-
zation methods for mRNAs and miRNAs, respectively 
and uploaded to the NCBI GEO database (Accession 
ID: GSE110966). The significance level of mRNAs and 
miRNAs was determined by applying an unpaired two-
tailed t test. Then the median values of each miRNA and 
mRNA were log2 transformed and the resulting miRNA 
P values were adjusted for multiple testing using Benja-
mini–Hochberg adjustment. In addition, the area under 
the receiver operating characteristic curve values for each 
miRNA were computed. For the significantly deregulated 
miRNAs and protein coding genes with P < 0.05 and fold 
change > 2 or < 1/2 in MFS patients compared to HV 
controls, we computed a Pearson correlation coefficient 
of expression for each mRNA–miRNA pair. Spearman’s 
correlations coefficient was used to correlate the clini-
cal parameters of MFS and the expression level of both 
validated miRNAs and mRNAs. Using the DataAssist™ 
Software v3.0 (Applied Biosystems), the fold-change and 
P value (unpaired t test with Welch’s correction) of each 
mRNA and miRNA was calculated.
Results
Patient characteristics
Among 19 females and 15 males included in the study, 
there were 22 patients with MVP, 6 patients with ectopia 
lentis and 14 patients who underwent aortic root replace-
ment because of aortic dissection or an aortic aneurysm 
(aortic root > 53  mm). Additional file  3: Table  S1 shows 
the clinical features of the MFS patients. The presented 
data refer to the largest diameters of the aortic root 
before surgery.
Correlation analysis of miRNA and mRNA between MFS 
patients and HV controls
As an initial analysis, we calculated the degree of corre-
lation based on Pearson’s correlation coefficient across 
samples from each group, i.e., MFS patients and HV con-
trols. The correlation plots are presented in Additional 
file 1: Figure S1 for miRNA and Additional file 2: Figure 
S2 for mRNA. In general, the correlation heatmaps illus-
trated that the correlation was strong (Pearson correla-
tion coefficient r of mostly > 0.80 and > 0.92 for miRNA 
and mRNA, respectively) in both MFS patients and HV 
controls, except for two samples which we identified as 
outliers in the mRNA data by applying Hampel’s rule for 
outlier detection [17]. These two samples and the corre-
sponding miRNA samples of the same MFS patients and 
HV controls were excluded from further analyses.
Differentially expressed miRNAs between MFS patients 
and HV controls
Using the high-throughput SurePrint G3 Human v16 
miRNA microarray platform, we screened the expression 
level of 1205 human mature miRNAs of miRBase v16. 
Following background correction and normalization, 
the miRNA expression levels from MFS patients and HV 
controls were identified. After excluding outliers, 7 MFS 
patients and 7 HV controls were considered for further 
analysis. Using quantile normalization, a total of 277 
miRNAs were detected in at least 25% of the samples in at 
least one group (filtering). By applying an un-paired two-
tailed t test for miRNAs that showed a significant change 
in the considered groups, 63 miRNAs showed statistical 
significance in MFS patients versus HV controls (Table 1) 
(P < 0.05. FDR adjusted). By considering only the differen-
tially expressed miRNAs with twofold or greater change 
in MFS patients versus HV controls, a total of 28 miR-
NAs were identified including 15 down-regulated and 13 
up-regulated miRNAs (P value < 0.05, fold change ≥ 2.0) 
(Table 1). To compare the relative expression level of the 
differentially expressed miRNAs, we used the hierarchi-
cal clustering of miRNAs and hierarchical clustering of 
samples based on average linkage and Euclidian distance 
of the significantly deregulated 63 miRNAs out of 1205 
miRNAs in MFS patients versus HV controls (Fig.  1). 
In general, hierarchical clustering revealed that MFS 
patients and HV controls were grouped into two distinct 
clusters, except for only one MFS (fell into the wrong 
cluster). Moreover, the heatmap showed that some miR-
NAs were expressed only in the MFS patients group and/
or expressed at a low level in HV controls and vice versa 
(Fig. 1).
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Table 1 Significantly expressed miRNAs in  the  blood of  patients with  MFS (n = 7) compared HVs controls (n = 7) 
as determined by microarray (unpaired two-tailed t test. P < 0.05, FDR adjusted)
miRNA Median log2 MFS Median log2 HVS Fold change Log2 fold change Regulation P value Adjusted P value AUC 
hsa‑miR‑4271 − 3.32 4.40 0.0047 − 7.72 Down 0.0037 0.0689 0.95
hsa‑miR‑3616‑3p − 3.32 4.15 0.0056 − 7.47 Down 0.0003 0.0149 0.96
hsa‑miR‑1228 − 3.32 3.80 0.0072 − 7.12 Down 0.0004 0.0149 0.98
hsa‑miR‑1238 − 3.32 3.17 0.0111 − 6.49 Down 0.0169 0.1552 0.84
hsa‑miR‑191 − 3.32 3.03 0.0123 − 6.35 Down 0.0450 0.2177 0.80
hsa‑miR‑1234 0.94 4.02 0.12 − 3.09 Down 0.0004 0.0149 0.98
hsa‑miR‑4313 0.69 3.39 0.15 − 2.70 Down 0.0468 0.2177 0.78
hsa‑miR‑139‑3p 0.65 3.15 0.18 − 2.50 Down 0.0001 0.0149 1.00
hsa‑miR‑874 2.83 4.76 0.26 − 1.92 Down 0.0042 0.0731 0.92
hsa‑miR‑564 4.70 5.90 0.43 − 1.20 Down 0.0003 0.0149 1.00
hsa‑miR‑940 3.06 4.21 0.45 − 1.15 Down 0.0004 0.0149 1.00
hsa‑miR‑1207‑5p 5.80 6.93 0.46 − 1.13 Down 0.0319 0.1878 0.83
hsa‑miR‑1280 1.64 2.73 0.47 − 1.10 Down 0.0048 0.0790 0.98
hsa‑miR‑181d 3.93 4.99 0.48 − 1.06 Down 0.0277 0.1845 0.80
hsa‑miR‑1275 3.77 4.80 0.49 − 1.03 Down 0.0014 0.0323 0.94
hsa‑miR‑3653 7.04 8.01 0.51 − 0.97 Down 0.0484 0.2177 0.85
hsa‑miR‑1268 5.18 6.07 0.54 − 0.88 Down 0.0239 0.1739 0.89
hsa‑miR‑320b 10.66 11.48 0.57 − 0.82 Down 0.0085 0.1242 0.92
hsa‑miR‑532‑3p 8.69 9.46 0.59 − 0.77 Down 0.0130 0.1444 0.84
hsa‑miR‑642b 3.17 3.93 0.59 − 0.76 Down 0.0179 0.1552 0.87
hsa‑miR‑4323 2.73 3.44 0.61 − 0.70 Down 0.0218 0.1675 0.87
hsa‑miR‑93 5.67 6.31 0.64 − 0.64 Down 0.0297 0.1871 0.80
hsa‑miR‑3162 6.83 7.46 0.65 − 0.63 Down 0.0068 0.1050 0.89
hsa‑miR‑3679‑5p 4.53 5.13 0.66 − 0.59 Down 0.0278 0.1845 0.87
hsa‑miR‑423‑5p 9.11 9.62 0.70 − 0.51 Down 0.0124 0.1433 0.86
hsa‑miR‑1225‑5p 6.16 6.67 0.70 − 0.51 Down 0.0287 0.1852 0.84
hsa‑miR‑3651 4.99 5.44 0.73 − 0.45 Down 0.0478 0.2177 0.81
hsa‑miR‑638 5.98 6.41 0.74 − 0.43 Down 0.0193 0.1575 0.86
hsa‑miR‑766 4.84 5.25 0.76 − 0.40 Down 0.0238 0.1739 0.91
hsa‑miR‑191 5.10 5.49 0.76 − 0.39 Down 0.0350 0.1978 0.83
hsa‑miR‑762 4.55 4.73 0.88 − 0.18 Down 0.0403 0.2106 0.78
hsa‑miR‑221 2.77 − 3.32 68.19 6.09 Up 0.0499 0.2177 0.18
hsa‑miR‑1288 2.53 − 3.32 57.95 5.86 Up 0.0344 0.1978 0.21
hsa‑miR‑3125 2.35 − 3.32 50.81 5.67 Up 0.0481 0.2177 0.21
hsa‑miR‑500b 2.27 − 3.32 48.35 5.60 Up 0.0142 0.1462 0.14
hsa‑miR‑200c 2.13 − 3.32 43.66 5.45 Up 0.0142 0.1462 0.14
hsa‑miR‑3200‑3p 2.07 − 3.32 41.98 5.39 Up 0.0280 0.1845 0.17
hsa‑miR‑3667‑5p 1.81 − 3.32 35.05 5.13 Up 0.0380 0.2067 0.14
hsa‑miR‑627 1.74 − 3.32 33.47 5.06 Up 0.0311 0.1878 0.14
hsa‑miR‑664 1.33 − 3.32 25.09 4.65 Up 0.0395 0.2106 0.20
hsa‑miR‑223 13.58 11.98 3.04 1.60 Up 0.0496 0.2177 0.15
hsa‑miR‑660 4.28 2.92 2.57 1.36 Up 0.0192 0.1575 0.08
hsa‑miR‑29c 4.59 3.33 2.41 1.27 Up 0.0177 0.1552 0.00
hsa‑miR‑7 4.62 3.56 2.09 1.06 Up 0.0357 0.1978 0.12
hsa‑miR‑29a 6.93 5.98 1.93 0.95 Up 0.0117 0.1407 0.04
hsa‑miR‑500a 5.70 4.80 1.87 0.90 Up 0.0008 0.0202 0.04
hsa‑miR‑23a 9.46 8.57 1.85 0.89 Up 0.0103 0.1364 0.06
hsa‑miR‑151‑5p 9.11 8.33 1.73 0.79 Up 0.0175 0.1552 0.09
hsa‑miR‑324‑5p 6.20 5.41 1.72 0.79 Up 0.0005 0.0149 0.05
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Differentially expressed genes between MFS patients 
and HV controls
Using the high-throughput SurePrint G3 Human Gene 
Expression v2 microarray platform, we screened the 
expression level of human 50,599 biological features of 
ENSEMBL release 52. Following background correc-
tion and normalization, the gene expression levels from 
MFS patients and HV controls were identified. Using 
variance stabilizing normalization (vsn) to the generated 
gene expression data, 58,717 transcripts were detected 
(no filtering). By applying an un-paired two-tailed t test 
for the transcripts that showed a significant change in 
the considered groups, we found 1662 transcripts with 
significant differences of MFS patients versus HV con-
trols (P < 0.05) (Additional file  3: Table  S2). By consid-
ering only the differentially expressed transcripts with 
1.5-fold or greater change in MFS patients versus HV 
controls, a total of 505 transcripts were identified includ-
ing 15 down-regulated and 490 up-regulated transcripts 
(P value < 0.05, fold change ≥ 1.5). Considering only the 
protein coding genes and removing different transcript 
variants, 296 genes out of 505 transcripts were identi-
fied, including 5 down-regulated and 291 up-regulated 
protein coding genes (Additional file  3: Table  S3). The 
number of significant protein coding genes with twofold 
or greater change in MFS patients versus HV controls 
was decreased including one down-regulated and 31 up-
regulated genes (P value < 0.05) (Table  2). Using hierar-
chical clustering with the Euclidian distance measure, we 
analyzed how the MFS patients and HV controls relate to 
each other. For this task, we used the 65 transcripts with 
the highest expression variances out of the 50,599 bio-
logical features. Figure 2 shows the resulting heatmap of 
the hierarchical clustering. In general, we observed two 
distinct clusters without overlap, with the first cluster 
containing only HV controls and the second cluster con-
taining only MFS patients.
Validation of candidate miRNAs and mRNAs by RT‑qPCR
In order to validate the results obtained from the micro-
array analysis, RT-qPCR was performed using a larger 
separate cohort of MFS patients and HV controls (MFS 
patients, n = 26 and HV controls, n = 26). Eighteen miR-
NAs were selected based on their differential expression 
level in MFS patients versus HV controls, and some of 
them were selected based on their known associations 
with cardiovascular diseases and MFS (listed in Table 1). 
In addition, 13 mRNAs were selected based on their 
known associations with cardiovascular diseases like 
mitral valve stenosis, myocardial infarction, ischemia and 
Table 1 (continued)
miRNA Median log2 MFS Median log2 HVS Fold change Log2 fold change Regulation P value Adjusted P value AUC 
hsa‑miR‑4306 12.57 11.84 1.66 0.73 Up 0.0161 0.1552 0.08
hsa‑miR‑186 6.78 6.10 1.60 0.68 Up 0.0261 0.1845 0.12
hsa‑miR‑502‑3p 5.53 4.87 1.58 0.66 Up 0.0005 0.0149 0.00
hsa‑miR‑23b 6.34 5.70 1.56 0.64 Up 0.0468 0.2177 0.18
hsa‑miR‑629 4.76 4.12 1.56 0.64 Up 0.0466 0.2177 0.20
hsa‑miR‑362‑5p 6.34 5.74 1.52 0.60 Up 0.0005 0.0149 0.02
hsa‑miR‑652 9.07 8.47 1.51 0.60 Up 0.0116 0.1407 0.16
hsa‑miR‑24 7.95 7.38 1.48 0.57 Up 0.0018 0.0392 0.01
hsa‑miR‑501‑3p 4.31 3.74 1.48 0.56 Up 0.0099 0.1364 0.04
hsa‑miR‑30e 5.97 5.49 1.39 0.48 Up 0.0027 0.0542 0.08
hsa‑miR‑331‑3p 10.09 9.62 1.38 0.46 Up 0.0205 0.1621 0.16
hsa‑miR‑451 16.51 16.05 1.38 0.46 Up 0.0004 0.0149 0.06
hsa‑miR‑532‑5p 5.94 5.53 1.33 0.41 Up 0.0318 0.1878 0.13
hsa‑miR‑103 10.66 10.25 1.33 0.41 Up 0.0478 0.2177 0.18
Each value represents the median of 7 MFS patients and 7 HV controls and ± standard deviation (STDV). Statistical analysis was performed with unpaired‑two‑tailed t 
test (P < 0.05). MFS Marfan syndrome, HVs healthy volunteers; AUC area under the receiver operating characteristic curve
(See figure on next page.)
Fig. 1 Unsupervised hierarchical clustering (Euclidian distance, complete linkage) of the 14 samples based on expression of the 63 with significant 
highest variance out of the 1205 miRNAs. The heatmap shows miRNAs with high expression in red, miRNAs with low expression in green. The red 
lines indicate three main clusters of samples
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Table 2 Significantly expressed protein coding genes in  the  blood of  patients with  MFS (n = 7) compared HVs controls 
(n = 7) as determined by microarray (unpaired two-tailed t test. > 2.0-fold difference. P < 0.05)
Each value represents the median of 7 MFS patients and 7 HV controls and ± standard deviation (STDV). Statistical analysis was performed with unpaired‑two‑tailed t 
test (P < 0.05). MFS Marfan syndrome, HVs healthy volunteers; AUC area under the receiver operating characteristic curve
Gene Name NCBI accession code Median 
log2 
MFS
Median 
log2 
HVS
Fold change log2 Fold 
change
Regulation P value AUC 
POT1 (protection of telomeres 1) NM_015450 7.96 9.05 0.47 −1.09 Down 0.0002 1.00
SIRPB1 (signal regulatory protein 
beta 1)
NM_001135844 11.30 8.96 5.08 2.34 Up 0.0474 0.16
HBZ (hemoglobin subunit zeta) NM_005332 8.71 6.47 4.73 2.24 Up 0.0132 0.16
MYOM2 (myomesin 2) NM_003970 8.38 6.50 3.67 1.87 Up 0.0372 0.14
ITGB3 (integrin subunit beta 3) NM_000212 9.23 7.38 3.62 1.86 Up 0.0392 0.08
MX1 (MX dynamin like GTPase 1) NM_002462 12.89 11.36 2.89 1.53 Up 0.0383 0.16
DYSF (dysferlin) NM_003494 10.49 9.04 2.74 1.45 Up 0.0149 0.08
CCR1 (C‑C motif chemokine receptor 
1)
NM_001295 12.91 11.50 2.66 1.41 Up 0.0217 0.12
IFIT2 (interferon induced protein with 
tetratricopeptide repeats 2)
NM_001547 11.56 11.33 1.17 0.23 Up 0.0317 0.14
LRG1 (leucine rich alpha‑2‑glycopro‑
tein 1)
NM_052972 11.14 9.85 2.45 1.29 Up 0.0181 0.16
TRANK1 (tetratricopeptide repeat and 
ankyrin repeat containing 1)
NM_014831 10.86 9.62 2.37 1.25 Up 0.0013 0.02
ZAN (zonadhesin (gene/pseudo‑
gene))
NM_173059 9.30 8.08 2.34 1.23 Up 0.0423 0.18
CRYAA (crystallin alpha A) NM_000394 9.30 8.08 2.34 1.23 Up 0.0329 0.18
NRGN (neurogranin) NM_006176 12.69 11.52 2.25 1.17 Up 0.0356 0.12
RNF213 (ring finger protein 213) NM_020914 8.24 7.70 1.46 0.55 Up 0.0377 0.18
LIMK2 (LIM domain kinase 2) NM_001031801 9.31 8.16 2.22 1.15 Up 0.0181 0.14
MFN2 (mitofusin 2) NM_014874 5.49 5.18 1.24 0.31 Up 0.0288 0.20
CTTN (cortactin) NM_005231 9.51 8.36 2.21 1.14 Up 0.0268 0.16
MX2 (MX dynamin like GTPase 2) NM_002463 12.60 11.52 2.11 1.07 Up 0.0157 0.12
CD14 (CD14 molecule) NM_001174104 15.04 13.97 2.10 1.07 Up 0.0332 0.16
GRN (granulin precursor) NM_002087 15.83 14.76 2.10 1.07 Up 0.0258 0.16
RNF222 (ring finger protein 222) NM_001146684 5.29 5.01 1.22 0.28 Up 0.0336 0.14
MVP (major vault protein) NM_017458 14.55 13.49 2.08 1.06 Up 0.0046 0.08
CXCL5 (C‑X‑C motif chemokine ligand 
5)
NM_002994 8.88 7.83 2.07 1.05 Up 0.0455 0.18
CTNNA1 (catenin alpha 1) NM_001903 9.08 8.05 2.05 1.04 Up 0.0309 0.16
MMP9 (matrix metallopeptidase 9) NM_004994 13.20 12.14 2.07 1.05 Up 0.0456 0.20
SOCS3 (suppressor of cytokine signal‑
ing 3)
NM_003955 9.47 8.43 2.05 1.03 Up 0.0472 0.20
GBP2 (guanylate binding protein 2) NM_004120 11.49 10.46 2.04 1.03 Up 0.0097 0.08
GNL3L (G protein nucleolar 3 like) NM_019067 8.33 7.93 1.32 0.41 Up 0.0325 0.20
CLU (clusterin) NM_001831 9.71 8.69 2.02 1.02 Up 0.0423 0.22
SELL (selectin L) NM_000655 14.93 13.93 2.00 1.00 Up 0.0011 0.04
OSM (oncostatin M) NM_020530 9.18 8.19 2.00 1.00 Up 0.0414 0.14
Fig. 2 Unsupervised hierarchical clustering (Euclidian distance, complete linkage) of the 14 samples based on expression of the 65 transcripts with 
the highest expression variances out of the 50,599 biological features. The heatmap shows transcripts with high expression in red, transcript with 
low expression in green. The red lines indicate three main clusters of samples
(See figure on next page.)
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acute coronary syndrome, and some had been observed 
to be differentially expressed with twofold or greater 
change in MFS patients versus HV controls in the micro-
array data (listed in Table  2). Considering the direction 
of expression changes, there was a general accordance 
between microarray and RT-qPCR data for the miRNAs 
and mRNAs tested. In detail, RT-qPCR validated the 
results of the microarray analysis for 11 out of 18 miR-
NAs with regards both to the direction of expression 
changes and to the significance of different expressions 
between MFS patients and HV controls, including one 
significantly down-regulated miRNA (miR-1234-3p) and 
10 significantly up-regulated miRNAs (miR-151-5p, miR-
200c, miR-24, miR-30e, miR-324-5p, miR-362-5p, miR-
500b, miR-502-3p, miR-627, and miR-331-3p) (Fig.  3). 
Likewise for the mRNA analysis, 11 out of 13 mRNAs 
showed the same direction of expression changes in 
the RT-qPCR and in the microarray analysis. Of these 
11 miRNAs, 6 mRNAs were validated with regard to 
both the direction of expression changes and to the sig-
nificance of different expressions between MFS patients 
and HV controls including 5 significantly up-regulated 
mRNAs (DYSF, GBP2, LIMK2, MMP9, and MX1) and 
one significantly down-regulated mRNA (POT1) (Fig. 4).
Inverse correlation between miRNA and target mRNA
To further understand the relationship between 
miRNA and mRNA changes, and to specifically identify 
potentially relevant miRNA–mRNA target interac-
tions, we calculated the Pearson correlation coefficient 
for every stably expressed miRNA and every protein 
coding gene that was significantly deregulated with a 
fold change of < 0.5/> 1.5. This computation yielded 11 
significant negative combinations (P < 0.05) with a cor-
relation range between −  0.62 and −  0.89 (Table  3). 
MiR-1234-3p showed the highest number of significant 
correlations followed by an intermediate group consist-
ing of miR-324-5p, miR-151-5p, miR-200c-3p, miR-
200c-3p, miR-362-5p, miR-502-3p and miR-627-5p. A 
number of genes involved in mitral valve stenosis, myo-
cardial infection, ischemia and acute coronary syndrome 
exhibited a statistically significantly correlation between 
miRNA and mRNA expression. In addition, based on 
microarray data and RT-qPCR, miR-1234-3p was down-
regulated and LIMK2, DYSF, GBP2, and MMP9 were 
up-regulated whereas one mRNA (POT1) was down-reg-
ulated and miR-324-5p, miR-151-5p, miR-200c-3p, miR-
200c-3p, miR-362-5p, miR-502-3p and miR-627-5p were 
up-regulated.
Correlation between the clinical parameters 
and expression levels of miRNA and mRNA
We further analyzed the correlations between the vali-
dated 11 miRNAs and 6 mRNAs by RT-qPCR and vari-
ous clinical parameters of MFS. We found that the 
expression levels of 7 miRNAs including miR-151-5p, 
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Fig. 3 Validation of differentially expressed miRNAs in the blood of MFS patients (n = 26) compared to HV controls (n = 26) as determined by 
RT‑qPCR (P < 0.05). Mean ΔCt MFS and HV controls (Lower ΔCt, higher expression level). RNAU6B as an endogenous control for normalization, 
Unpaired‑two‑tailed t tests and ± standard deviation (STDV) were used to evaluate differences in expression. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001
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miR-24, miR-30e, miR-324-5p, miR-362-5p, miR-500b, 
and miR-502-3p significantly correlated with the age of 
patients with MFS (Table  4) (P < 0.05). In contrast, no 
significant correlation was observed between the expres-
sion levels of these 7 miRNAs and the aortic root status 
of patients with MFS. However, there was a significant 
correlation between the expression level of miR-200c (P 
value = 0.015) and a borderline significant correlation 
with miR-151-5p, miR-324-5p and miR-500b and aor-
tic root status (Z-score) of patients with MFS. Statisti-
cally significant correlations were observed between 7 
miRNAs including miR-151-5p, miR-24, miR-30e, miR-
324-5p, miR-500b, miR-502-3p, and miR-627) and the 
LVEDD. There was no significant correlation between 
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Fig. 4 Validation of differentially expressed mRNAs in the blood of MFS patients (n = 26) compared to HV controls (n = 26) as determined by 
RT‑qPCR (P < 0.05). Mean ΔCt MFS and HV controls (Lower ΔCt, higher expression level). β‑Actin as an endogenous housekeeping gene for 
normalization, Unpaired‑two‑tailed t tests and ± standard deviation (STDV) were used to evaluate differences in expression. *P ≤ 0.05; **P ≤ 0.01; 
***P ≤ 0.001
Table 3 Significant negative correlation between the identified miRNA and mRNA by microarray (un-paired two-tailed t 
test < 0.5/> 1.5-fold difference, P < 0.05)
miRNA mRNA P value correlation Correlation Fold change 
miRNA
P value miRNA Fold change 
mRNA
P value mRNA
hsa‑miR‑1234 LIMK2 0.00001 − 0.89 0.12 0.00038 2.22 0.01813
hsa‑miR‑1234 DYSF 0.00018 − 0.85 0.12 0.00038 2.74 0.01491
hsa‑miR‑1234 GBP2 0.00143 − 0.78 0.12 0.00038 2.04 0.00973
hsa‑miR‑1234 MMP9 0.00382 − 0.74 0.12 0.00038 2.15 0.03885
hsa‑miR‑324‑5p POT1 0.00670 − 0.69 1.72 0.00050 0.47 0.00017
hsa‑miR‑151‑5p POT1 0.00728 − 0.68 1.73 0.01754 0.47 0.00017
hsa‑miR‑200c POT1 0.01132 − 0.65 43.66 0.01425 0.47 0.00017
hsa‑miR‑362‑5p POT1 0.01281 − 0.64 1.52 0.00045 0.47 0.00017
hsa‑miR‑502‑3p POT1 0.01590 − 0.63 1.58 0.00054 0.47 0.00017
hsa‑miR‑500b POT1 0.01868 − 0.62 48.35 0.01419 0.47 0.00017
hsa‑miR‑627 POT1 0.01868 − 0.62 33.47 0.03109 0.47 0.00017
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the validated target mRNAs and the clinical parameters 
of MFS. Furthermore, we also assessed the significance 
of the differences of the validated 11 miRNAs in MFS 
patients without MVP compared with patients with MVP 
using the Wilcoxon test. Out of these 11 miRNAs, miR-
331-3p showed a significant down-regulation in patients 
with MVP compared to patients without MVP (P < 0.05). 
MiR-200c showed a borderline significant decrease in 
MFS patients with MVP compared with patients without 
MVP (P = 0.060).
Classification and overrepresentation analysis
Considering only the protein coding genes and remov-
ing of different transcript variants, 292 genes out of 296 
were grouped according to PANTHER protein class, 
GO Molecular Function, GO Biological Process and GO 
cellular components annotations. The complete classi-
fications can be found in the Additional file 3: Table S4. 
In detail, after applying Bonferroni correction for mul-
tiple testing, there were statistically significant path-
ways within the 292 genes differentially expressed in 
the MFS patients, displaying apoptosis signaling path-
way (P value = 1.54E−03), JAK/STAT signaling path-
way (P value = 1.78E−02), integrin signaling pathway (P 
value = 1.92E−02) and angiogenesis (P value = 3.50E−02) 
(Table 5).
Discussion
In this study, we found 13 miRNAs and 31 mRNAs with 
significantly increased expression levels and 15 miRNAs 
and one single mRNA (POT1) with significantly 
decreased expression level in patients with MFS com-
pared with HV controls. In a cohort of independent MFS 
patients and HV controls, 11 miRNAs and 6 mRNAs 
were validated. These data show that miRNA and mRNA 
expression levels in the blood of patients with MFS differ 
Table 4 Correlation between  clinical parameters and  validated miRNA and  mRNA expression levels by  RT-qPCR 
in patients with MFS P < 0.05)
LVEDD left ventricular end diastolic diameter, MVP mitral valve prolapse. P values were calculated using unpaired‑two‑tailed t test (P < 0.05). *P values were calculated 
using Wilcoxon test (P < 0.05)
Italic—significant with adjusted P‑value
Bold Italic—borderline significant with adjusted P‑value
Parameters Marfan syndrome patients Healthy volunteers
Age (MFS patients) Aortic root status
(Z score)
LVEDD MVP Age
miRNA Correlation P value Correlation P value Correlation P value P value* Correlation P value
hsa‑miR‑1234 0.003 0.988 0.063 0.761 − 0.075 0.716 0.732 − 0.122 0.554
hsa‑miR‑151‑5p 0.519 0.007 0.375 0.059 0.496 0.010 0.979 0.055 0.789
hsa‑miR‑200c 0.370 0.063 0.473 0.015 0.213 0.295 0.060 − 0.220 0.279
hsa‑miR‑24 0.496 0.010 0.281 0.164 0.420 0.033 0.654 − 0.194 0.342
hsa‑miR‑30e 0.565 0.003 0.230 0.258 0.472 0.015 0.517 − 0.030 0.883
hsa‑miR‑324‑5p 0.510 0.008 0.350 0.079 0.457 0.019 0.391 − 0.019 0.927
hsa‑miR‑362‑5p 0.413 0.036 0.216 0.289 0.383 0.053 0.673 0.024 0.906
hsa‑miR‑500b 0.440 0.024 0.384 0.053 0.456 0.019 0.812 − 0.003 0.987
hsa‑miR‑502‑3p 0.505 0.008 0.260 0.200 0.425 0.030 0.816 0.036 0.860
hsa‑miR‑627 0.310 0.123 0.291 0.149 0.423 0.032 0.816 0.010 0.961
hsa‑miR‑331‑3p 0.307 0.127 0.333 0.097 0.015 0.942 0.041 − 0.243 0.231
Parameters Marfan syndrome patients Healthy volunteers
Age Aortic root status
(Z score)
LVEDD MVP Age
mRNA Correlation P value Correlation P value Correlation P value P value Correlation P value
DYSF 0.123 0.550 0.087 0.672 − 0.010 0.963 0.958 0.186 0.385
GBP2 0.200 0.326 0.071 0.729 − 0.198 0.332 0.816 0.080 0.710
LIMK2 0.003 0.989 − 0.142 0.489 − 0.241 0.235 0.916 0.135 0.530
MMP9 0.276 0.173 0.272 0.178 − 0.042 0.840 0.460 0.295 0.162
MX1 0.071 0.732 − 0.142 0.489 0.019 0.926 0.897 0.073 0.736
POT1 − 0.028 0.891 − 0.041 0.842 − 0.306 0.129 0.510 − 0.075 0.727
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from HV controls and that distinct differences in specific 
miRNA expression patterns can be further explored as 
potential biomarkers for differentiating between patients 
with MFS and HV controls. A distinctive non-invasive 
surrogate biomarker for MFS would be of high clinical 
value, as mutation analysis of the huge (65 exons) FBN1 
gene is still relatively expensive and time-consuming and 
therefore restricted to phenotypically recognized Ghent-
positive patients. An affordable screening test for MFS 
would likely detect a considerable number of atypical 
MFS who currently remain undiagnosed. Moreover, our 
investigation provides a comprehensive analysis of the 
gene expression pattern in patients with MFS as com-
pared to HV controls, suggesting that non-pathogenic 
variants of other genes than FBN1 may significantly influ-
ence the phenotype, and explain the often striking clini-
cal variation among members of a given MFS family. The 
identification of these genes may lead to a possible novel 
signature related to MFS, provide new prognostic param-
eters and ultimately even generate targets for novel 
approaches to chemoprevention of complications beyond 
currently unsatisfying medical treatment options [18]. 
Intriguingly, many of the biological pathways identified, 
such as apoptosis signaling [19], JAK/STAT signaling 
[20], integrin signaling [21] and angiogenesis pathways 
[22], have been associated with development of cardio-
vascular complications in MFS and its related diseases 
including aortic and pulmonary artery dilation as well as 
mitral valve prolapse. Among the identified deregulated 
mRNAs, some genes play a role in cardiomyocyte differ-
entiation and remodeling during acute myocardial infarc-
tion and in dilated cardiomyopathy (DCM). For example, 
patients suffering from DCM show a strong and lasting 
increase of oncostatin M (OSM) gene expression level 
and signaling [23]. Moreover, significant changes in clus-
terin [24] gene level have been detected in patients with 
acute myocardial infarction (AMI) [25] and increased 
levels of selectin L (SELL) are associated with ischemic 
stroke [26]. The JAK/STAT pathway is negatively regu-
lated by the suppressor of cytokine signaling (SOCS) pro-
tein, and the myocardium-specific suppressor of cytokine 
signaling 3 (SOCS3) gene plays a key role in the develop-
ment of left ventricular (LV) remodeling after AMI [27]. 
In agreement with the higher expression level of C-X-C 
motif chemokine ligand 5 (CXCL5) in the blood of 
patients with MFS, CXCL5 showed an increased expres-
sion level in the plasma of patients with coronary artery 
disease. Recent studies have showed that CXCL5 and its 
receptors are implicated in congestive heart failure and 
ischemic stroke, making CXCL5 a candidate gene for 
potential future therapy strategies in cardiovascular dis-
eases [28–30]. CXCL5 has also been reported to be up-
regulated in abdominal aortic aneurysm (AAA) [31]. 
Matrix metalloproteinase 9 (MMP) was shown to be up-
regulated in the blood of MFS patients by microarray and 
RT-qPCR in our analysis. MMP9 showed a significant 
inverse correlation with hsa-miR-1234, which also was 
identified in the MFS patients [9]. A proteolytic degrada-
tion of the extracellular matrix of the aortic wall by an 
upregulation MMPs has been shown to be involved in the 
pathogenesis of TAA and AAA and also contributes to 
the histologic changes found in the aortic wall of patients 
with MFS [32, 33]. The expression of MMP9 has been 
shown to be up-regulated in the vascular wall of human 
AAA [34, 35] and also in aneurysm tissue in a mouse 
model of MFS [32]. Interestingly, Balistreri et  al., found 
potential associations of SNPs in the MMP9 gene 
[rs3918242 (−1562C/T MMP-9)] degenerative forms of 
mitral valve diseases (MVDs), concluding that genetic 
variants in MMP9 play a role in MVD in MFS patients 
[36]. Together with our data, showing an up-regulation of 
MMP9 in the blood of MFS patients compared to con-
trols, indicate that MMP9 may represent a potential bio-
marker and therapeutic target to reduce the growth rate 
Table 5 Pathways significantly enriched for  the  identified protein coding genes in  the  blood of  patients with  MFS 
compared to HV controls (adjusted P value < 0.05)
Pathways resulted significantly over‑represented by the identified protein coding genes. P values were tested using Fisher exact test and adjusted using a Bonferroni 
correction test. MFS Marfan syndrome, HVs healthy volunteers
a  Number of genes in the reference list that map to this PANTHER classification category
b  Number of genes in the target genes list that map to this PANTHER classification category
c  Expected value is the number of genes that could be expected in target genes list for this PANTHER category based on the reference list
PANTHER classification pathways Number of genes Over‑/under‑
represented (±)
Fold enrichment P value
Reference  lista Target  listb Expectedc
Apoptosis signaling pathway (P00006) 119 10 1.68 + 5.96 0.00154
JAK/STAT signaling pathway (P00038) 17 4 0.24 + 16.69 0.00210
Integrin signalling pathway (P00034) 194 11 2.73 + 4.02 0.01920
Angiogenesis (P00005) 174 10 2.45 + 4.08 0.03500
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of TAAs in MFS patients. Doxycyclin and statins have 
proven to be effective inhibitors of MMPs [37, 38] and 
have shown therapeutic benefits in both TAA and AAA 
patients [39, 40]. However, data on MFS patients as well 
as large randomized trials are still lacking, making these 
drugs promising candidates for future investigations in 
MFS. Our data, showing a significant inverse correlation 
of miR-1234 and MMP9 indicate that a down-regulation 
of this miRNA may be involved in the up-regulation 
MMP9 in MFS. We demonstrate a significantly up-regu-
lated expression of the LIM kinase 2 (LIMK2) which also 
inversely correlated with miR-1234. LIMK2 regulates 
dynamic changes of the actin cytoskeleton by phospho-
rylating cofilin and thereby inactivating its F-actin depo-
lymerizing activity [41]. It was shown in mouse models 
that an activation of LIMK2 is associated with a disturbed 
flow in the aortic arch and disturbs endothelial cell (EC) 
barrier function, which was reversed by inhibition of 
LIMK2 with m-calpain [42]. An up-regulation of LIMK2 
likely linked to a down-regulation of miR-1234 in the 
blood of MFS patients, which was demonstrated in our 
study, therefore may be related to elevated levels of vas-
cular wall shear stress in the thoracic aorta of MFS 
patients [43] and be associated with endothelial dysfunc-
tion in MFS. Since effective LIMK2 inhibition has already 
been shown to improve endothelial function in animal 
models [42]. LIMK2 may represent a promising target for 
future investigations in MFS patients. Our data shown a 
significant up-regulation of guanylate binding protein-2 
(GBP-2) and a significant inverse correlation with miR-
1234 in the blood of MFS patients compared to controls. 
Human guanylate binding proteins (GBPs) are a class of 
large GTPases which are induced by cytokines like Inter-
feron alpha/gamma, Interleukin-1 and TNF-alpha [44]. 
GBP-2 has not yet been investigated as comprehensively 
as GBP-1, but shares 75% sequence identity with this iso-
form [45] which has been shown to be actively secreted 
by ECs [46]. Patients with rheumatic diseases like rheu-
matoid arthritis, systemic lupus erythematosus [22], and 
systemic sclerosis, which are characterized by a chronic 
inflammatory vessel activation, show reduced levels of 
GBP-1 in their peripheral blood [44]. In a rat arterio-
venous (AV) loop model, it has been shown that GBP-1 
inhibits endothelial cell progenitor migration and leads to 
endothelial cell dysfunction [44]. An up-regulation of 
GBP-2 in the blood of MFS patients is likely reflects the 
vascular pathology and disturbed endothelial cell func-
tion in these patients. A significant up-regulation and 
inverse correlation to miR-1234 in the blood of MFS 
patients compared to controls was also shown for dysfer-
lin (DYSF). Mutations in DYSF lead to limb-girdle mus-
cular dystrophy type 2B and Miyoshi myopathy. DYSF, 
which is expressed in human ECs, has been shown to 
form a complex with platelet endothelial cellular adhe-
sion molecule-1 (PECAM-1), thereby preventing its pro-
teosomal degradation [47]. Since PECAM-1 is a ligand of 
αVβ3-integrin and a promotor of angiogenesis, these data 
are in line with our observation of an enrichment of gene 
sets for angiogenesis and integrin signaling in the blood 
of MFS patients. DYSF is induced in vitro by TNF-alpha 
and has also been shown to be up-regulated in the blood 
vessels of patients with multiple sclerosis representing 
increased vascularinflammation and a disturbed blood–
brain barrier [48]. It seems likely that an overexpression 
of DYSF in the blood of MFS patients, as with GBP-2, 
represents vascular inflammation in these patients and 
may be a potential biomarker for the severity of vascular 
pathologies in MFS warranting further investigations. 
The gene encoding for protection of telomeres 1 (POT1) 
was the only significantly down-regulated gene in the 
blood of MFS patients (fold-change ≤ 2) compared to 
controls and exhibited inverse correlations with 7 miR-
NAs. POT1 binds single-stranded DNA as a heterodimer 
with tripeptidyl peptidase 1 (TPP1) and promotes telom-
erase-mediated telomere extension. Reduced telomere 
length is recognized as a hallmark of cardiovascular aging 
and as a biomarker for and TAA and dissections [49, 50]. 
It has to date not been investigated whether telomere 
length plays a role in the pathogenesis of MFS. The 
reduced expression of POT1 in the blood of MFS patients 
demonstrated in our study, however, indicates, that accel-
erated cardiac ageing may be present in MFS, which may 
be reflected in reduced telomere length and POT1 
expression. Among the miRNAs inversely correlating 
with POT1, miR-362 has been linked to the degree of 
inflammation in samples from abdominal aortic aneu-
rysms [51]. Moreover, miR-500 was shown to be deregu-
lated in degenerative mitral valve disease [52] and 
miR-502 was also up-regulated in the sera of patients 
with congestive heart failure [53]. Some genes which we 
found to be up-regulated in the blood of MFS patients 
compared to controls play a role in cardiomyocyte differ-
entiation and remodeling during AMI as well as in DCM. 
Patients with DCM show a strong and lasting increase of 
oncostatin M (OSM) gene expression [23]. Moreover, sig-
nificant changes in clusterin [24] have been detected in 
patients with AMI [25] and increased levels of selectin L 
(SELL) are associated with ischemic stroke [26]. The JAK/
STAT pathway is negatively regulated by the suppressor 
of cytokine signaling (SOCS) protein, and the myocar-
dium-specific suppressor of cytokine signaling 3 (SOCS3) 
gene plays a key role in the development of left ventricu-
lar (LV) remodeling after AMI [27]. In agreement with 
the higher expression level of C-X-C motif chemokine 
ligand 5 (CXCL5) in the blood of patients with MFS, 
CXCL5 showed an increased expression level in the 
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plasma of patients with coronary artery disease. Recent 
studies have shown that CXCL5 is up-regulated in 
abdominal aortic aneurysms (AAA) [31], making it a can-
didate for potential future anti-inflammatory therapy 
strategies in MFS. We identified three miRNAs, namely 
miR-151-5p, miR-324-5p, and miR-500b, which corre-
lated significantly with the Z-score and the LVEDD of 
MFS patients. MiR-24 and miR-30e correlated only with 
the LVEDD of MFS patients in our study. MiR-24 has 
been reported to be up-regulated in tissue from thoracic 
aortic aneurysms [54] and the miR-30-family was shown 
to be up-regulated in tissue from thoracic aortic dissec-
tions and abdominal aortic aneurysms [55, 56]. Interest-
ingly miR-331-3p, which has been linked to cardiac 
hypertrophy [57] and miR-200, which also has been 
linked to cardiovascular disease [58], were down-regu-
lated in MFS patients with MVP compared with patients 
without MVP. MiR-200c-3p also showed an inverse cor-
relation to POT1 in our study. These deregulated miR-
NAs may serve as potential future biomarkers in MFS 
after conformational analysis in studies with larger sam-
ple sizes. MiRNA and mRNA profiles measured in PAX-
gene blood samples comes to a greater extent from the 
cellular components of the blood, i.e. leukocytes and 
erythrocytes, and only to a lesser extent from cell-free 
RNA. Therefore, the expression changes we identified in 
our study presumably reflect rather changes in the blood 
cells of the patients rather than expression changes in 
solid tissue, i.e. bone. One of the MFS clinical manifesta-
tions is the musculoskeletal system (typically tall stature 
with arachnodactyly) and patients with MFS also have 
significant musculoskeletal phenotypes which may affect 
the marrow cavity and subsequently influence the hemat-
opoiesis process. Therefore, it is conceivable that changes 
in miRNA and mRNA expression profile in the blood of 
MFS patients might be the results of differences in the 
hematopoiesis process in MFS patients compared to 
healthy controls. Another line of thinking is, that differ-
ences in the mRNA and miRNA profiles might originate 
from differences in blood flow kinetics between MFS 
patients and controls. It is known that altered blood pres-
sure has an impact on miRNA expression profile, as 
shown by Neth et al. [59]. Aortic dilatation and structural 
cardiac anomalies like MVP in MFS patients exposes the 
vascular endothelium to altered hemodynamic forces, 
which may indirectly influence miRNA and mRNA pro-
files in the blood cells of MFS patients due to different 
blood flow velocities compared to healthy individuals.
Limitations of our study are related to a relatively small 
sample size. Moreover, our analysis focused only on the 
main diagnostic criteria such as FBN1 positivity, aortic 
root dilatation and lens dislocation and revealed correla-
tions of miRNA expression to cardiovascular features such 
as aortic root dilatation and mitral valve prolapse. Skeletal 
features which are characterized by a highly variable age 
of onset are heterogeneous and have been considered as 
secondary diagnostic criteria according to the modified 
Ghent criteria. Certainly, the skeletal features are impor-
tant leading diagnostic criteria for further evaluation of the 
patients suspected to have Marfan disease. Correlation of 
miRNA expression to skeletal abnormalities has to be per-
formed in future studies with larger cohorts of patients 
with definitive and highly characterized main skeletal fea-
tures. Future studies also have to investigate whether the 
observed miRNA expression profiles are specific to MFS or 
also relate to other syndromes with familial thoracic aortic 
aneurysm like Loeys–Dietz syndrome, Shprintzen–Gold-
berg syndrome or mutations in ACTA2.
Conclusions
We present the first study investigating miRNA and mRNA 
expression patterns in the peripheral blood of MFS patients 
in comparison with HV controls. A strong deregulation of 
both miRNA and mRNA expression profiles was present 
in MFS patients including multiple genes with high rel-
evance to cardiovascular pathogenesis and diseases. Four 
genes associated with vascular pathology and inflammation 
namely MMP9, LIMK2, GBP-2, and DYSF were up-regu-
lated in MFS patients and showed inverse correlations with 
miR-1234. POT-1 was down-regulated and inversely corre-
lated with 7 miRNAs indicating a potential role of telomere 
length in the pathogenesis of MFS. These genes represent 
promising candidates for future investigations aiming at 
prognostic biomarkers for cardiovascular manifestations 
in MFS as well as targets for novel therapeutic approaches. 
Apart from the particular considerations as to the value 
of the observed distinctive miRNA/mRNA patterns for 
diagnosis and prognosis of MFS patients, our study fun-
damentally highlights the extreme breadth of molecu-
lar downstream effects initiated by a constitutional single 
point mutation in a monogenic heritable condition. Pleiot-
ropy also has an as yet underestimated molecular dimen-
sion that may provide insights into how complex seemingly 
“simple” monogenic traits actually are.
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